Reduced-intensity SCT for chronic active EBV infection: excellent outcomes should trigger future investigations on how EBV-positive recipient cells are eradicated.
Gottschalk
S
S
Department of Pediatrics and Immunology, Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA. smgottsc@txccc.org
D002908:Chronic Disease; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D018380:Hematopoietic Stem Cell Transplantation; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology* / Q000821:virology; D012107:Research Design; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome